Moderna Inc (MRNA)
Days of sales outstanding (DSO)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Receivables turnover | 6.64 | 11.88 | 5.69 | 0.57 | 4.92 | |
| DSO | days | 54.95 | 30.73 | 64.12 | 636.49 | 74.24 |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 6.64
= 54.95
The Days of Sales Outstanding (DSO) for Moderna Inc have shown significant fluctuations over the past five years. In particular, there was a notable improvement in DSO from 2020 to 2021, where it decreased from a very high 640.83 days to 65.13 days. This improvement suggests that Moderna was able to collect its accounts receivable more efficiently in 2021 compared to the prior year.
However, in 2022, the DSO decreased even further to 35.07 days, indicating a continued enhancement in the company's collection efficiency. It is worth noting that the DSO for 2023 increased slightly to 53.35 days compared to 2022, but it still remained at a relatively low level.
Overall, the trend in DSO for Moderna Inc reflects a positive development in managing accounts receivable, with the company showing improvements in collecting sales revenue efficiently over the past few years. This trend is indicative of effective credit and collection policies, which have contributed to enhancing the company's liquidity and working capital management.
Peer comparison
Dec 31, 2023